Department of Pulmonology, Leiden University Medical Center, Leiden, The Netherlands.
Department of Biomedical Data Science, section Medical Statistics, Leiden University Medical Center, Leiden, The Netherlands.
Histopathology. 2023 Apr;82(5):650-663. doi: 10.1111/his.14831. Epub 2022 Nov 9.
Lymph node micrometastases could be one of the reasons for the high recurrence rate after complete surgical resection in stage I-IIIA non-small cell lung cancer (NSCLC). The standard evaluation of a single haematoxylin and eosin (H&E) slide of a paraffin-embedded section of a lymph node is insufficient for the detection of micrometastases, and there is a need for additional histopathological evaluation. The association of lymph node micrometastases with survival remains as yet unresolved. The aim of this systematic review and meta-analysis is to investigate if lymph node micrometastases and isolated tumour cells in patients with stage I-IIIA NSCLC, detected with multiple sectioning and/or immunohistochemistry (IHC) and/or reverse transcriptase polymerase chain reaction (RT-PCR), are associated with overall survival (OS) and disease-free survival (DFS) after surgical resection. We performed a meta-analysis of time-to-event outcomes based on 15 articles using ancillary techniques to detect micrometastases. We extracted the OS and DFS every 3-6 months after surgery, for patients with and without occult lymph node micrometastasis, from the survival curves published in each article. These data were used to reconstruct OS and DFS for 'micrometastasis' and 'no micrometastasis' groups. Based on all included studies that used IHC, serial sectioning, or RT-PCR, we found a 5-year OS of 55% (micrometastasis) vs. 75% (no micrometastasis), and a 5-year DFS of 53% (micrometastasis) vs. 75% (no micrometastasis). Patients with stage I-IIIA NSCLC with lymph node micrometastases detected by ancillary histopathological and molecular techniques have a significantly poorer OS and DFS compared to patients without lymph node micrometastases.
淋巴结微转移可能是 I 期-IIIA 期非小细胞肺癌(NSCLC)患者完全手术后高复发率的原因之一。对石蜡包埋淋巴结切片的单个苏木精和伊红(H&E)染色的标准评估不足以检测微转移,需要额外的组织病理学评估。淋巴结微转移与生存的关系尚未解决。本系统评价和荟萃分析的目的是研究在 I 期-IIIA 期 NSCLC 患者中,使用多切片和/或免疫组织化学(IHC)和/或逆转录聚合酶链反应(RT-PCR)检测到的淋巴结微转移和孤立肿瘤细胞是否与手术后的总生存期(OS)和无病生存期(DFS)相关。我们使用辅助技术对 15 篇文章进行了时间事件结果的荟萃分析,以检测微转移。我们从发表的每篇文章的生存曲线中提取了手术后每 3-6 个月 OS 和 DFS,包括有和无隐匿性淋巴结微转移的患者。这些数据用于为“微转移”和“无微转移”组重建 OS 和 DFS。基于所有使用 IHC、连续切片或 RT-PCR 的纳入研究,我们发现 5 年 OS 为 55%(微转移)vs. 75%(无微转移),5 年 DFS 为 53%(微转移)vs. 75%(无微转移)。通过辅助组织病理学和分子技术检测到淋巴结微转移的 I 期-IIIA 期 NSCLC 患者的 OS 和 DFS 明显较差。
Health Technol Assess. 2006-9
Cochrane Database Syst Rev. 2018-2-6
Cochrane Database Syst Rev. 2022-9-26
Cochrane Database Syst Rev. 2005-1-25
Cochrane Database Syst Rev. 2021-5-4
Cochrane Database Syst Rev. 2022-1-7
Cochrane Database Syst Rev. 2025-1-29
Onco Targets Ther. 2023-2-15